Literature DB >> 19560901

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.

Rebecca Schennach-Wolff1, Markus Jäger, Florian Seemüller, Michael Obermeier, Thomas Messer, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G Schmidt, Wolfgang Gaebel, Wolfgang Huff, Isabella Heuser, Wolfgang Maier, Matthias R Lemke, Eckart Rüther, Gerd Buchkremer, Markus Gastpar, Hans-Jürgen Möller, Michael Riedel.   

Abstract

BACKGROUND: To assess criteria and to identify predictive factors for functional outcome. The criteria should cover all domains proposed by the Remission in Schizophrenia Working Group.
METHOD: PANSS ratings were used to evaluate the symptomatic treatment outcome of 262 inpatients with schizophrenia spectrum disorders within a naturalistic multicenter trial. Functional remission was defined as a GAF score >61 (Global Assessment of Functioning Scale), SOFAS score >61 (Social and Occupational Functioning Scale) and a SF-36 mental health subscore >40 (Medical Outcomes Study-Short Form Health Survey). Multivariate logistic regression and CART analyses were used to determine valid clinical and sociodemographic predictors.
RESULTS: In total, 52 patients (20%) fulfilled the criteria for functional remission, 125 patients (48%) achieved symptomatic resolution and when criteria for functional remission and symptomatic resolution were combined 33 patients (13%) achieved complete remission. Younger age, employment, a shorter duration of illness, a shorter length of current episode, less suicidality, and a lower PANSS negative and global subscore at admission were predictive of functional remission. The regression model showed a predictive value of more than 80%.
CONCLUSIONS: A significant association was found between functional remission and symptomatic resolution, indicating reasonable validity of the proposed definition for functional outcome. The revealed predictors for functional treatment outcome emphasize the need for psychosocial and vocational rehabilitation in schizophrenic patients.

Entities:  

Mesh:

Year:  2009        PMID: 19560901     DOI: 10.1016/j.schres.2009.05.032

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  23 in total

1.  Predictors and Prevalence of Recovery and Remission for Consumers Discharged from Mental Hospitals in a Chinese Society.

Authors:  Daniel K W Young; Petrus Y N Ng; Jiayan Pan
Journal:  Psychiatr Q       Date:  2017-12

Review 2.  Functional outcomes in schizophrenia: employment status as a metric of treatment outcome.

Authors:  Rebecca Schennach; Richard Musil; Hans-Jürgen Möller; Michael Riedel
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

3.  Family Functioning in First-Episode and Chronic Psychosis: The Role of Patient's Symptom Severity and Psychosocial Functioning.

Authors:  Katerina Koutra; Sofia Triliva; Theano Roumeliotaki; Maria Basta; Christos Lionis; Alexandros N Vgontzas
Journal:  Community Ment Health J       Date:  2015-08-19

4.  The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients.

Authors:  Katja Ribbe; Heidi Friedrichs; Martin Begemann; Sabrina Grube; Sergi Papiol; Anne Kästner; Martin F Gerchen; Verena Ackermann; Asieh Tarami; Annika Treitz; Marlene Flögel; Lothar Adler; Josef B Aldenhoff; Marianne Becker-Emner; Thomas Becker; Adelheid Czernik; Matthias Dose; Here Folkerts; Roland Freese; Rolf Günther; Sabine Herpertz; Dirk Hesse; Gunther Kruse; Heinrich Kunze; Michael Franz; Frank Löhrer; Wolfgang Maier; Andreas Mielke; Rüdiger Müller-Isberner; Cornelia Oestereich; Frank-Gerald Pajonk; Thomas Pollmächer; Udo Schneider; Hans-Joachim Schwarz; Birgit Kröner-Herwig; Ursula Havemann-Reinecke; Jens Frahm; Walter Stühmer; Peter Falkai; Nils Brose; Klaus-Armin Nave; Hannelore Ehrenreich
Journal:  BMC Psychiatry       Date:  2010-11-10       Impact factor: 3.630

5.  Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.

Authors:  Hong Liu-Seifert; Haya Ascher-Svanum; Olawale Osuntokun; Kai Yu Jen; Juan Carlos Gomez
Journal:  BMC Psychiatry       Date:  2011-05-17       Impact factor: 3.630

6.  The importance of measuring psychosocial functioning in schizophrenia.

Authors:  Sofia Brissos; Andrew Molodynski; Vasco Videira Dias; Maria Luísa Figueira
Journal:  Ann Gen Psychiatry       Date:  2011-06-24       Impact factor: 3.455

7.  Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study.

Authors:  Gebra B Cuyún Carter; Denái R Milton; Haya Ascher-Svanum; Douglas E Faries
Journal:  BMC Psychiatry       Date:  2011-08-26       Impact factor: 3.630

8.  Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome.

Authors:  Marcelo Valencia; Ana Fresán; Yoram Barak; Francisco Juárez; Raul Escamilla; Ricardo Saracco
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-10       Impact factor: 2.570

9.  The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia.

Authors:  Ryoko Nakagawa; Takashi Ohnishi; Hisanori Kobayashi; Akihide Wakamatsu; Ai Tanimura; Kazuo Morita; Toshio Yamaoka; Hideo Usui; Yoshimasa Ogawa; Akiko Fujino; Kazutake Yoshizawa
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-22       Impact factor: 2.570

10.  Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?

Authors:  Sirijit Suttajit; Suwanna Arunpongpaisal; Manit Srisurapanont; Nuntika Thavichachart; Ronnachai Kongsakon; Sunanta Chantakarn; Vasu Chantarasak; Apichat Jariyavilas; Piyadit Jaroensook; Khanogwan Kittiwattanagul; Osot Nerapusee
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-29       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.